Ewha Med J.  2021 Oct;44(4):117-121. 10.12771/emj.2021.44.4.117.

Diagnosis and Treatment of Central Precocious Puberty

• Choi HS
• Kim HS
• Chae HW

• KMID: 2521820
• DOI: http://doi.org/10.12771/emj.2021.44.4.117

Abstract

A notable secular trend in early puberty onset has been described over the past few decades. Also, the prevalence and incidence of precocious puberty is increasing not only in Korea, but also around the world. The manifestation of secondary sex characteristics before 8 years in girls and 9 years in boys is defined as precious puberty. The causes of precocious puberty can be classified as gonadotropin releasing hormone (GnRH)-dependent, also known as central precocious puberty (CPP), or GnRH-independent. Evaluation of patient with precocity requires detailed examination of the clinical manifestation, GnRH stimulation test, and imaging of the central nervous system if indicated. The standard treatment for CPP is GnRH agonist, which is beneficial for adequate pubertal development and preservation of final adult height. In this paper, we investigate the diagnosis and adequate treatment of CPP.

Keyword

Precocious puberty; Gonadotropin-releasing hormone; Puberty

Reference

1. Euling SY, Herman-Giddens ME, Lee PA, Selevan SG, Juul A, Sorensen TI, et al. 2008; Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings. Pediatrics. 121 Suppl 3:S172–S191. DOI: 10.1542/peds.2007-1813D. PMID: 18245511.

2. Sorensen K, Mouritsen A, Aksglaede L, Hagen CP, Mogensen SS, Juul A. 2012; Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr. 77:137–145. DOI: 10.1159/000336325. PMID: 22508036.

3. Biro FM, Galvez MP, Greenspan LC, Succop PA, Vangeepuram N, Pinney SM, et al. 2010; Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls. Pediatrics. 126:e583–e590. DOI: 10.1542/peds.2009-3079. PMID: 20696727. PMCID: PMC4460992.

4. Eckert-Lind C, Busch AS, Petersen JH, Biro FM, Butler G, Brauner EV, et al. 2020; Worldwide secular trends in age at pubertal onset assessed by breast development among girls: a systematic review and meta-analysis. JAMA Pediatr. 174:e195881. DOI: 10.1001/jamapediatrics.2019.5881. PMID: 32040143. PMCID: PMC7042934.

5. Marshall WA, Tanner JM. 1969; Variations in pattern of pubertal changes in girls. Arch Dis Child. 44:291–303. DOI: 10.1136/adc.44.235.291. PMID: 5785179. PMCID: PMC2020314.

6. Kaplowitz PB, Oberfield SE. 1999; Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics. 104(4 Pt 1):936–941. DOI: 10.1542/peds.104.4.936. PMID: 10506238.

7. Partsch CJ, Sippell WG. 2001; Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Update. 7:292–302. DOI: 10.1093/humupd/7.3.292. PMID: 11392376.

8. Brauner EV, Busch AS, Eckert-Lind C, Koch T, Hickey M, Juul A. 2020; Trends in the incidence of central precocious puberty and normal variant puberty among children in Denmark, 1998 to 2017. JAMA Netw Open. 3:e2015665. DOI: 10.1001/jamanetworkopen.2020.15665. PMID: 33044548. PMCID: PMC7550972.

9. Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, et al. 2019; Incidence and prevalence of central precocious puberty in Korea: an epidemiologic study based on a national database. J Pediatr. 208:221–228. DOI: 10.1016/j.jpeds.2018.12.022. PMID: 30857777.

10. Elders MJ, Scott CR, Frindik JP, Kemp SF. 1997; Clinical workup for precocious puberty. Lancet. 350:457–458. DOI: 10.1016/S0140-6736(05)63075-9.

11. De Sanctis V, Corrias A, Rizzo V, Bertelloni S, Urso L, Galluzzi F, et al. 2000; Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab. 13 Suppl 1:687–693. DOI: 10.1515/JPEM.2000.13.S1.687.

12. Suh J, Choi HS, Kwon A, Chae HW, Kim HS. 2020; Effect of agricultural pesticide on precocious puberty in urban children: an exploratory study. Clin Exp Pediatr. 63:146–150. DOI: 10.3345/cep.2019.00416. PMID: 32024321. PMCID: PMC7170788.

13. Jung MK, Choi HS, Suh J, Kwon A, Chae HW, Lee WJ, et al. 2019; The analysis of endocrine disruptors in patients with central precocious puberty. BMC Pediatr. 19:323. DOI: 10.1186/s12887-019-1703-4. PMID: 31493798. PMCID: PMC6731581.

14. Lee JE, Jung HW, Lee YJ, Lee YA. 2019; Early-life exposure to endocrine-disrupting chemicals and pubertal development in girls. Ann Pediatr Endocrinol Metab. 24:78–91. DOI: 10.6065/apem.2019.24.2.78. PMID: 31261471. PMCID: PMC6603611.

15. Carel JC, Leger J. 2008; Clinical practice. Precocious puberty. N Engl J Med. 358:2366–2377. DOI: 10.1056/NEJMcp0800459. PMID: 18509122.

16. Neely EK, Hintz RL, Wilson DM, Lee PA, Gautier T, Argente J, et al. 1995; Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr. 127:40–46. DOI: 10.1016/S0022-3476(95)70254-7.

17. Ab Rahim SN, Omar J, Tuan Ismail TS. 2020; Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review. Ann Pediatr Endocrinol Metab. 25:152–155. DOI: 10.6065/apem.2040004.002. PMID: 32871650. PMCID: PMC7538306.

18. Kandemir N, Demirbilek H, Ozon ZA, Gonc N, Alikasifoglu A. 2011; GnRH stimulation test in precocious puberty: single sample is adequate for diagnosis and dose adjustment. J Clin Res Pediatr Endocrinol. 3:12–17. DOI: 10.4274/jcrpe.v3i1.03. PMID: 21448328. PMCID: PMC3065310.

19. Kim HK, Kee SJ, Seo JY, Yang EM, Chae HJ, Kim CJ. 2011; Gonadotropin-releasing hormone stimulation test for precocious puberty. Korean J Lab Med. 31:244–249. DOI: 10.3343/kjlm.2011.31.4.244. PMID: 22016677. PMCID: PMC3190002.

20. Oerter KE, Uriarte MM, Rose SR, Barnes KM, Cutler GB Jr. 1990; Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab. 71:1251–1258. DOI: 10.1210/jcem-71-5-1251. PMID: 2121771.

21. Fuqua JS. 2013; Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 98:2198–2207. DOI: 10.1210/jc.2013-1024. PMID: 23515450.

22. Kumar M, Mukhopadhyay S, Dutta D. 2015; Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: an Indian perspective. Indian J Endocrinol Metab. 19:228–235. DOI: 10.4103/2230-8210.149316. PMID: 25729684. PMCID: PMC4319262.

23. Lee DM, Chung IH. 2019; Morning basal luteinizing hormone, a good screening tool for diagnosing central precocious puberty. Ann Pediatr Endocrinol Metab. 24:27–33. DOI: 10.6065/apem.2019.24.1.27. PMID: 30943677. PMCID: PMC6449618.

24. Heo S, Lee YS, Yu J. 2019; Basal serum luteinizing hormone value as the screening biomarker in female central precocious puberty. Ann Pediatr Endocrinol Metab. 24:164–171. DOI: 10.6065/apem.2019.24.3.164. PMID: 31607109. PMCID: PMC6790867.

25. Chalumeau M, Hadjiathanasiou CG, Ng SM, Cassio A, Mul D, Cisternino M, et al. 2003; Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule. J Pediatr. 143:445–450. DOI: 10.1067/S0022-3476(03)00328-7.

26. Carel JC, Lahlou N, Roger M, Chaussain JL. 2004; Precocious puberty and statural growth. Hum Reprod Update. 10:135–147. DOI: 10.1093/humupd/dmh012. PMID: 15073143.

27. Cho AY, Ko SY, Lee JH, Kim EY. 2020; Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 25:24–30. DOI: 10.6065/apem.2020.25.1.24. PMID: 32252213. PMCID: PMC7136506.

28. Mul D, Hughes IA. 2008; The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 159 Suppl 1:S3–S8. DOI: 10.1530/EJE-08-0814. PMID: 19064674.

29. Kim MS, Koh HJ, Lee GY, Kang DH, Kim SY. 2019; Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy. Ann Pediatr Endocrinol Metab. 24:116–123. DOI: 10.6065/apem.2019.24.2.116. PMID: 31261476. PMCID: PMC6603606.

30. Bertelloni S, Mul D. 2008; Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 10:525–534. DOI: 10.1111/j.1745-7262.2008.00409.x. PMID: 18478155.

31. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, Williams RH. 2020. Williams textbook of endocrinology. 14th ed. Elsevier;Philadelphia: DOI: 10.33029/9704-4951-6-PEND-1-848.

32. Kaplowitz PB. 2009; Treatment of central precocious puberty. Curr Opin Endocrinol Diabetes Obes. 16:31–36. DOI: 10.1097/MED.0b013e328320a650. PMID: 19104235.

33. Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, et al. 2019; Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 91:357–372. DOI: 10.1159/000501336. PMID: 31319416.

34. Tanaka T, Hibi I, Kato K, Saito S, Shimizu N, Suwa S, et al. 1991; A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group. Endocrinol Jpn. 38:369–376. DOI: 10.1507/endocrj1954.38.369. PMID: 1839379.

35. Jin HY, Choi JH, Yoo HW. 2010; Evaluation of efficacy of GnRH agonist on predicted adult height (PAH) in patients with central precocious puberty using two different dosages. J Korean Soc Pediatr Endocrinol. 15:120–125.

36. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, et al. ESPE-LWPES GnRH Analogs Consensus Conference Group. 2009; Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 123:e752–e762. DOI: 10.1542/peds.2008-1783. PMID: 19332438.

37. Akaboshi S, Takeshita K. 2000; A case of atypical absence seizures induced by leuprolide acetate. Pediatr Neurol. 23:266–268. DOI: 10.1016/S0887-8994(00)00181-8.

38. Inman M, Hursh BE, Mokashi A, Pinto T, Metzger DL, Cummings EA. 2013; Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty. Horm Res Paediatr. 80:64–68. DOI: 10.1159/000351028. PMID: 23859950.

39. Chung LY, Nam HK, Rhie YJ, Huh R, Lee KH. 2020; Prevalence of idiopathic scoliosis in girls with central precocious puberty: effect of a gonadotropin-releasing hormone agonist. Ann Pediatr Endocrinol Metab. 25:92–96. DOI: 10.6065/apem.1938164.082. PMID: 32615688. PMCID: PMC7336263.

40. Eugster EA. 2019; Treatment of central precocious puberty. J Endocr Soc. 3:965–972. DOI: 10.1210/js.2019-00036. PMID: 31041427. PMCID: PMC6486823.

41. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, et al. 1999; Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 141:140–144. DOI: 10.1530/eje.0.1410140. PMID: 10427157.

42. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. 1999; Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab. 84:1973–1978. DOI: 10.1210/jcem.84.6.5647. PMID: 10372696.

43. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. 2001; Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 86:4711–4716. DOI: 10.1210/jcem.86.10.7915. PMID: 11600530.

44. Jung MK, Song KC, Kwon AR, Chae HW, Kim DH, Kim HS. 2014; Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. Ann Pediatr Endocrinol Metab. 19:214–219. DOI: 10.6065/apem.2014.19.4.214. PMID: 25654068. PMCID: PMC4316408.

45. Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F. 1999; Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab. 84:449–452. DOI: 10.1210/jcem.84.2.5431. PMID: 10022399.